Silver Book Fact

In one study, deep-brain stimulation for Parkinson’s patients significantly reduced their required dosages of antiparkinsonian medications, consequently decreasing their medication costs by 32% 1 year after surgery, and 39% 2 years after.

Charles, P. David, Bimal P. Padaliya, William J. Newman, Chadler E. Gill, Cassondra D. Covington, John F. Yang, Stephanie A. So, Michael G. Tramontana, Peter E. Kondrad, and Thomas L. Davis. Deep Brain Stimulation of the Subthalamic Nucleus Reduces Antiparkinsonian Medication Costs. Parkinsonism & Related Disorders. 2004; 10(8): 475-9. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=15542007&dopt=AbstractPlus

Reference

Title
Deep Brain Stimulation of the Subthalamic Nucleus Reduces Antiparkinsonian Medication Costs
Publication
Parkinsonism & Related Disorders
Publication Date
2004
Authors
Charles, P. David, Bimal P. Padaliya, William J. Newman, Chadler E. Gill, Cassondra D. Covington, John F. Yang, Stephanie A. So, Michael G. Tramontana, Peter E. Kondrad, and Thomas L. Davis
Volume & Issue
Volume 10, Issue 8
Pages
475-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Early Gene Therapy Studies Show Promise for Parkinson’s Disease
     
  • Medicare Costs, Slowed Progression  
  • The U.S. Food and Drug Administration has approved 5 drugs for the treatment of Alzheimer’s disease. These drugs have been found to temporarily slow the worsening of Alzheimer’s symptoms for…  
  • According to one Parkinson’s expert, a 10% slowing of Parkinson’s disease progression would save $327 million per year.  
  • Valuing a QALY at $175,000, new drugs that would produce a 5-year delay in Alzheimer’s disease onset for all new cases between 2010 and 2050 would yield a benefit of…